{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"CR = complete remission; CRc = composite complete remission rate; CRh = complete remission with partial hematologic recovery, CRi = complete remission with incomplete hematologic recovery; MLFS = morphologic leukemia free state; ORR = overall response rate; SD = stable disease Categories defined by the 2022 European LeukemiaNet (ELN) recommendations.","groups":[{"description":"Participants who had failed standard of care including Venetoclax and Gilteritining based therapies. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.","id":"OG000","title":"Phase 2, Schedule B, Cohort 1:360+150 mg"},{"description":"Participants who had failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days.\n\nThe same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.","id":"OG001","title":"Phase 2, Schedule B, Cohort 2: 360+150 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients Evaluable for Efficacy Analysis:This population included all enrolled participants in Phase 2 who were treated at RP2D \\& had ≥1 hematologic assessment. Participants who had early death or withdrew before response assessment, or had technically suboptimal BM sample, were non-evaluable for response and excluded from efficacy dataset. For Cohort 1 and Cohort 2, only subset of subjects with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population.","reportingStatus":"POSTED","timeFrame":"At Screening; Day 1 of Cycle 2 and Cycle 3; and Day 1 at subsequent even cycle; up to End of Treatment visit (within 7 days of the final dose of study drug), up to 17 months","title":"Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).","type":"PRIMARY","unitOfMeasure":"Participants"}